Home > Insider Trading > Filing (0001209191-23-025128)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1754068	Allovir Inc.	ALVR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1337845	Vikas Sinha	C/O Allovir, Inc. 1100 Winter Street Waltham MA 02451	See Remarks	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-04-19	1,217	$3.71	1,186,521	No	4	S	Direct
Common Stock	Disposition	2023-04-20	1,466	$3.63	1,185,055	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	16,674,766	Indirect	Shares held by ElevateBio LLC

Footnotes

Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84.Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.62 to $3.64.Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have sharedvoting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except tothe extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficialownership of all of the reported shares for purposes of Section 16 or for any other purpose.